dc.contributor.author | Mugwanya, Kenneth K | |
dc.contributor.author | Wyatt, Christina | |
dc.contributor.author | Celum, Connie | |
dc.contributor.author | Donnell, Deborah | |
dc.contributor.author | Mugo, Nelly | |
dc.contributor.author | Kiarie, James N. | |
dc.contributor.author | Ronald, Allan | |
dc.contributor.author | Baeten, Jared | |
dc.date.accessioned | 2015-06-13T13:33:40Z | |
dc.date.available | 2015-06-13T13:33:40Z | |
dc.date.issued | 2015-02-26 | |
dc.identifier.citation | Mugwanya, Kenneth K., Wyatt, Christina [untranslated] Celum, Connie [untranslated] Donnell, Deborah., Mugo, Nelly., Kiarie, James N., Ronald, Allan (2015).Reversibility of kidney function decline in HIV-1–uninfected men and women using preexposure prophylaxis.Croi 2015. Conference on retroviruses and opportunistic infections. February 23-26, 2015 (Abstract 981). seattle, washington | en_US |
dc.identifier.uri | http://hdl.handle.net/11295/84750 | |
dc.description.abstract | Background: Tenofovir disoproxil fumarate pre-exposure prophylaxis (PrEP) use is associated with a small but statistically significant decline in estimated glomerular filtration
rate (eGFR). We investigated the occurrence and reversibility of eGFR decline among HIV-1 uninfected adults discontinuing PrEP.
Methods: Data are from the Partners PrEP Study, a trial of daily oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC)/TDF PrEP among 4747 African HIV-1 uninfected
men and women who had normal baseline renal parameters. Renal function was assessed at baseline, month 1, and then quarterly while on study medication and up to 2 monthly
visits in the post-study drug follow-up phase. eGFR was calculated using the Chronic Kidney Disease Epidemiolgy Collaboration Equation.
Results: A total of 3944 individuals had a post-study drug visit within 12 weeks of drug discontinuation (1277 in TDF group, 1309 in FTC-TDF group, and 1358 for placebo); 64%
were male, median age was 34 (range 18–64) years, and mean eGFR was similar at baseline (p>0.05). Median time on study drug was 33 (IQR 25–36) months. Compared to
placebo (Figure 1), mean eGFR for PrEP was slightly but statistically significantly lower at the last on-treatment visit (128 mL/min/173m2 for TDF and FTC-TDF vs 130 mL/min/173m2
for placebo; p≤0.01). This difference reversed to within baseline levels by 4 weeks after PrEP discontinuation (130 mL/min/173m2 for TDF, 129 mL/min/173m2 for FTC-TDF vs 130 mL/
min/173m2 for placebo eGFR; p>0.2 for all). Consistent patterns were observed for serum phosphorus
Conclusions: In this large study among African men and women who had a median TDF-exposure of 33 months, the reduction in mean eGFR was small and returned to within
baseline levels by 4 weeks after discontinuation of TDF-based PrEP | en_US |
dc.language.iso | en | en_US |
dc.publisher | University of Nairobi | en_US |
dc.title | Reversibility of kidney function decline in HIV-1–uninfected men and women using preexposure prophylaxis | en_US |
dc.type | Presentation | en_US |
dc.type.material | en | en_US |